好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Automatically segmented medulla oblongata volume as a surrogate for spinal cord atrophy in multiple sclerosis
Multiple Sclerosis
P5 - Poster Session 5 (5:30 PM-6:30 PM)
15-029

To assess the association between automatically measured medulla oblongata volume (MOV) and spinal cord cross-sectional area (SC-CSA) as well as their associations with clinical disability in multiple sclerosis (MS).

Spinal cord atrophy is well known to be associated with clinical disability in MS. Manually-measured MOV on brain MRI has previously been proposed as a potential proxy for spinal cord atrophy.

161 MS patients were scanned on 1.5T MRI brain and cervical spinal cord sequences were collected. 126  patients had relapsing-remitting MS (RRMS) and 35 had secondary progressive MS (SPMS) disease course. Clinical disability was quantified via the Expanded Disability Status Scale (EDSS). MOV and SC-CSA (measured between C2-C3) were automatically calculated using FreeSurfer and Spinal Cord Toolbox, respectively. RRMS and SPMS patients were compared with respect to both MRI-derived measures. Correlations between MOV and SC-CSA and their associations with EDSS were also assessed. 

Compared to RRMS patients, SPMS patients presented with smaller MO volume (p=.003) and smaller C2-C3 CSA (p<.0001). When considering the entire cohort, MOV and SC-CSA were correlated (r=.574, p<.0001). A similar correlation was found in RRMS patients (r=.570, p<.0001) but somewhat weaker in SPMS patients (r=.355, p=.037). For the whole sample, correlations were found between MOV (rs= -.446,p<.0001) and SC-CSA (rs = -.572, p<.0001) with EDSS. For RRMS patients, the associations were similar in degree (rs = -.329, p=.001 and rs=-.332, p=.002, respectively) whereas for SPMS patients, the strength of the correlations diverged (rs = -.364,p=.029 and rs= -.779, p<.0001, respectively).

Our findings demonstrate that MOV correlates well with SC-CSA and can be reliably segmented in an automatic fashion. Moreover, MOV may potentially serve as a surrogate measure for SC atrophy in RRMS when cervical spine MRI is not available.

Authors/Disclosures
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo)
PRESENTER
Prof. Bergsland has nothing to disclose.
Dejan Jakimovski, MD, PhD (Buffalo Neuroimaging Analysis Center, University at Buffalo) Dr. Jakimovski has nothing to disclose.
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo) Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center) The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.